{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:17:15Z","timestamp":1778635035668,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104279"],"award-info":[{"award-number":["82104279"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["252102311235"],"award-info":[{"award-number":["252102311235"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.dmd.2026.100274","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:43:44Z","timestamp":1773906224000},"page":"100274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neddylation inhibition sensitizes gastric cancer to 5-fluorouracil by targeting the post-translational stability of the metabolic enzyme dihydropyrimidine dehydrogenase"],"prefix":"10.1016","volume":"54","author":[{"given":"Qianqian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongzhao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linyue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8151-6558","authenticated-orcid":false,"given":"Siqi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dmd.2026.100274_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.dmd.2026.100274_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","article-title":"Gastric cancer treatment: recent progress and future perspectives","volume":"16","author":"Guan","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100274_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41575-022-00703-w","article-title":"Current developments in gastric cancer: from molecular profiling to treatment strategy","volume":"20","author":"Alsina","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dmd.2026.100274_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111285","article-title":"5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition","volume":"137","author":"Sethy","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.dmd.2026.100274_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10147-003-0319-7","article-title":"5-fluorouracil and dihydropyrimidine dehydrogenase","volume":"8","author":"Kubota","year":"2003","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100274_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1023\/A:1008337913456","article-title":"Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression","volume":"11","author":"Takenoue","year":"2000","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100274_bib7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.dmd.2026.100274_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100125","article-title":"Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature","volume":"6","author":"Hodroj","year":"2021","journal-title":"ESMO Open"},{"issue":"16","key":"10.1016\/j.dmd.2026.100274_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70124","article-title":"The role of DPYD and the effects of DPYD suppressor luteolin combined with 5-FU in pancreatic cancer","volume":"13","author":"Kato","year":"2024","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.dmd.2026.100274_bib10","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/ph18050727","article-title":"DPYD genotyping, fluoropyrimidine dosage and toxicity: an umbrella review of systematic reviews","volume":"18","author":"Otero-Torres","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.dmd.2026.100274_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1645188","article-title":"DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger","volume":"16","author":"Rosas-Alonso","year":"2025","journal-title":"Front Pharmacol"},{"issue":"45","key":"10.1016\/j.dmd.2026.100274_bib12","doi-asserted-by":"crossref","first-page":"28557","DOI":"10.1074\/jbc.272.45.28557","article-title":"Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein","volume":"272","author":"Kamitani","year":"1997","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.dmd.2026.100274_bib13","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/emboj\/17.8.2208","article-title":"A novel protein modification pathway related to the ubiquitin system","volume":"17","author":"Liakopoulos","year":"1998","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.dmd.2026.100274_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-019-0979-1","article-title":"Neddylation: a novel modulator of the tumor microenvironment","volume":"18","author":"Zhou","year":"2019","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.dmd.2026.100274_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41392-020-00226-3","article-title":"NEDD8-conjugating enzyme UBC12 as a novel therapeutic target in esophageal squamous cell carcinoma","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"10.1016\/j.dmd.2026.100274_bib16","article-title":"NNMT\/1-MNA promote cell-cycle progression of breast cancer by targeting UBC12\/Cullin-1-mediated degradation of P27 proteins","volume":"11","author":"Ma","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"16","key":"10.1016\/j.dmd.2026.100274_bib17","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1158\/1078-0432.CCR-15-2254","article-title":"Neddylation inhibition activates the extrinsic apoptosis pathway through ATF4-CHOP-DR5 axis in human esophageal cancer cells","volume":"22","author":"Chen","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100274_bib18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/bab.2112","article-title":"Role of neddylation in neurological development and diseases","volume":"69","author":"He","year":"2022","journal-title":"Biotechnol Appl Biochem"},{"issue":"10","key":"10.1016\/j.dmd.2026.100274_bib19","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1517\/13543784.2012.707192","article-title":"MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy","volume":"21","author":"Nawrocki","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"10.1016\/j.dmd.2026.100274_bib20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.18632\/oncotarget.27485","article-title":"Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment","volume":"11","author":"Misra","year":"2020","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.dmd.2026.100274_bib21","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3892\/mmr.2017.6305","article-title":"Neural precursor cell expressed, developmentally downregulated 8-activating enzyme inhibitor MLN4924 sensitizes colorectal cancer cells to oxaliplatin by inducing DNA damage, G2 cell cycle arrest and apoptosis","volume":"15","author":"Zheng","year":"2017","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.dmd.2026.100274_bib22","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1038\/s41467-022-30559-2","article-title":"Neddylation inhibition induces glutamine uptake and metabolism by targeting CRL3(SPOP) E3 ligase in cancer cells","volume":"13","author":"Zhou","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.dmd.2026.100274_bib23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41419-022-05292-9","article-title":"PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis"},{"issue":"8","key":"10.1016\/j.dmd.2026.100274_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.215","article-title":"The novel protective role of P27 in MLN4924-treated gastric cancer cells","volume":"6","author":"Zhang","year":"2015","journal-title":"Cell Death Dis"},{"issue":"13","key":"10.1016\/j.dmd.2026.100274_bib25","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-12-3212","article-title":"Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer","volume":"19","author":"Nawrocki","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.dmd.2026.100274_bib26","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1158\/0008-5472.CAN-12-0388","article-title":"The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth","volume":"72","author":"Luo","year":"2012","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100274_bib27","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1038\/s41467-023-38581-8","article-title":"ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer","volume":"14","author":"Wong","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.dmd.2026.100274_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13046-024-03085-w","article-title":"Neddylation activated TRIM25 desensitizes triple-negative breast cancer to paclitaxel via TFEB-mediated autophagy","volume":"43","author":"Zheng","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.dmd.2026.100274_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.113770","article-title":"Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy","volume":"270","author":"Cheng","year":"2021","journal-title":"J Ethnopharmacol"},{"issue":"17","key":"10.1016\/j.dmd.2026.100274_bib30","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1089\/ars.2013.5795","article-title":"Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy","volume":"21","author":"Zhao","year":"2014","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10.1016\/j.dmd.2026.100274_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41392-022-01182-w","article-title":"A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100274_bib32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-023-01485-7","article-title":"Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions","volume":"16","author":"Fu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.dmd.2026.100274_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241237607","article-title":"A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis","volume":"15","author":"Kong","year":"2024","journal-title":"Ther Adv Hematol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100274_bib34","doi-asserted-by":"crossref","first-page":"7929","DOI":"10.3390\/ijms24097929","article-title":"A promising way to overcome temozolomide resistance through inhibition of protein neddylation in glioblastoma cell lines","volume":"24","author":"Brandt","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"14","key":"10.1016\/j.dmd.2026.100274_bib35","doi-asserted-by":"crossref","first-page":"23713","DOI":"10.18632\/oncotarget.15785","article-title":"dUTPase inhibition augments replication defects of 5-Fluorouracil","volume":"8","author":"Hagenkort","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.dmd.2026.100274_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s10147-003-0330-z","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines","volume":"8","author":"Omura","year":"2003","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.dmd.2026.100274_bib37","article-title":"Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)","volume":"13","author":"Zhang","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.dmd.2026.100274_bib38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jare.2025.01.006","article-title":"Activation of sphingosine-1-phosphate receptor 2 (S1PR2) upregulates dihydropyrimidine dehydrogenase (DPD) expression in colon cancer cells","volume":"77","author":"Guo","year":"2025","journal-title":"J Adv Res"},{"issue":"10","key":"10.1016\/j.dmd.2026.100274_bib39","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.7150\/ijbs.113709","article-title":"Harnessing natural products to surmount drug resistance in gastric cancer: mechanisms and therapeutic perspectives","volume":"21","author":"Wang","year":"2025","journal-title":"Int J Biol Sci"},{"issue":"4","key":"10.1016\/j.dmd.2026.100274_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.149","article-title":"Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation","volume":"5","author":"Kang","year":"2014","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.dmd.2026.100274_bib41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrm3919","article-title":"Protein neddylation: beyond cullin-RING ligases","volume":"16","author":"Enchev","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100274_bib42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-020-00444-9","article-title":"The regulation of protein translation and its implications for cancer","volume":"6","author":"Song","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"31","key":"10.1016\/j.dmd.2026.100274_bib43","doi-asserted-by":"crossref","first-page":"21640","DOI":"10.1074\/jbc.M513034200","article-title":"Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases","volume":"281","author":"Oved","year":"2006","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.dmd.2026.100274_bib44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41419-020-2472-6","article-title":"Neddylation of sterol regulatory element-binding protein 1c is a potential therapeutic target for nonalcoholic fatty liver treatment","volume":"11","author":"Ju","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.dmd.2026.100274_bib45","article-title":"DNA polymerase \u03b7 is regulated by mutually exclusive mono-ubiquitination and mono-NEDDylation","volume":"13","author":"Moreno","year":"2024","journal-title":"Preprint. bioRxiv. Posted online October"},{"issue":"6","key":"10.1016\/j.dmd.2026.100274_bib46","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4161\/cc.11.6.19559","article-title":"The ubiquitin E1 enzyme Ube1 mediates NEDD8 activation under diverse stress conditions","volume":"11","author":"Leidecker","year":"2012","journal-title":"Cell Cycle"},{"issue":"15","key":"10.1016\/j.dmd.2026.100274_bib47","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2411429122","article-title":"Neddylation modification stabilizes LC3B by antagonizing its ubiquitin-mediated degradation and promoting autophagy in skin","volume":"122","author":"Xu","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.dmd.2026.100274_bib48","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.7150\/thno.78876","article-title":"Targeting cullin neddylation for cancer and fibrotic diseases","volume":"13","author":"He","year":"2023","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.dmd.2026.100274_bib49","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/ijc.33113","article-title":"UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis","volume":"147","author":"Heo","year":"2020","journal-title":"Int J Cancer"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:03:03Z","timestamp":1778634183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0090955626000437"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100274","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neddylation inhibition sensitizes gastric cancer to 5-fluorouracil by targeting the post-translational stability of the metabolic enzyme dihydropyrimidine dehydrogenase","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100274"}}